Pancreatic Neuroendocrine Tumor Biomarker and Survival Data

58 surgically resected primary pancreatic neuroendocrine tumor samples were analyzed for biomarker expression and clinical outcomes. The dataset includes immunohistochemical evaluation of ATRX, DAXX, ARX/PDX1, and SSTR2a/5, with associations to recurrence-free survival, cancer-specific survival, and overall survival. It was authored by Oana A. Ciobanu and last updated on 2026-05-11.

Use Cases

• Predicting ATRX/DAXX mutation status based on tumor size cutoff of 2.45 cm.
• Associating somatostatin receptor SSTR5 expression with longer median overall survival.
• Comparing biomarker expression prevalence between functional and nonfunctional tumor groups.
• Analyzing recurrence-free survival based on immunohistochemical biomarker scores.

Strengths

• Includes quantitative expression scores and receiver operating characteristic curve analysis for 58 patient samples.
• Reports specific survival metrics, such as a median OS of 73 months for SSTR5-positive tumors.
• Defines a tumor size cutoff of 2.45 cm with 96.9% sensitivity for predicting ATRX/DAXX loss.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 137.4 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Retrospective analysis of 58 surgically resected primary PanNET samples with immunohistochemical evaluation.

Freshness

Last updated 2026-05-11 04:23:37; freshness should be verified.